Observational studyInternal and emergency medicine2026
The systemic immune-inflammation biomarkers in Sjögren's disease: associations with disease activity and extraglandular manifestations in a multicentric Italian cohort.
Observational study in Internal and emergency medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From immune activation to symptom burden: mechanisms and translational implications of immune-symptom uncoupling in Sjögren's disease.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sjögren's disease (SjD) is an autoimmune exocrinopathy characterized by heterogeneous extraglandular manifestations (EGM). The systemic immune-inflammation biomarkers, including the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII), have been proposed as indicators of the inflammatory burden, but data in SjD remain limited. This retrospective multicenter Italian study aimed to evaluate the NLR, PLR, and SII in exocrine SjD patients and across specific EGM. Consecutive patients fulfilling the 2016 ACR/EULAR classification criteria for SjD and with available full blood count data were included. Patients were classified as having exocrine or extraglandular SjD according to the presence of specific EGM. The NLR, PLR, and SII were calculated and compared across disease phenotypes and activity levels. Among 239 SjD patients (96% female, median age 59 years), 70% presented at least one EGM. Extraglandular SjD patients had longer disease duration (p = 0.04) and higher frequencies of hypergammaglobulinemia (p = 0.05), anti-nuclear antibodies (p = 0.0003), anti-SSA antibodies (p = 0.04), and rheumatoid factor (p = 0.04). Overall, the median NLR, PLR, and SII did not differ between exocrine and extraglandular SjD. However, patients with arthritis showed higher NLR (p = 0.02), PLR (p < 0.05), and SII (p = 0.005), while patients with interstitial lung disease displayed higher SII (p = 0.01). Extraglandular SjD patients with moderate-to-high disease activity showed increased NLR and SII (p = 0.004, for both). Systemic immune-inflammation biomarkers are inexpensive, readily available and easy to calculate. The NLR, PLR, and SII are associated with specific inflammatory phenotypes and higher disease activity in Italian SjD patients. Prospective studies are warranted to confirm these preliminary findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.